Annual report pursuant to Section 13 and 15(d)

REVENUES - Percentage by Customer (Details)

v3.20.4
REVENUES - Percentage by Customer (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Grifols | fostamatinib      
Disaggregation of Revenue [Line Items]      
Expected rollout term 18 months    
Sales | Customer concentration risk | Grifols      
Disaggregation of Revenue [Line Items]      
Percentage 41.00% 8.00%  
Sales | Customer concentration risk | ASD Healthcare and Oncology Supply      
Disaggregation of Revenue [Line Items]      
Percentage 30.00% 37.00% 17.00%
Sales | Customer concentration risk | McKesson Specialty Care Distribution Corporation      
Disaggregation of Revenue [Line Items]      
Percentage 23.00% 30.00% 11.00%
Sales | Customer concentration risk | Kissei      
Disaggregation of Revenue [Line Items]      
Percentage   3.00% 69.00%
Sales | Customer concentration risk | Daiichi      
Disaggregation of Revenue [Line Items]      
Percentage 2.00%    
Sales | Customer concentration risk | Aclaris      
Disaggregation of Revenue [Line Items]      
Percentage   9.00%  
Sales | Customer concentration risk | Celgene      
Disaggregation of Revenue [Line Items]      
Percentage   6.00%